Concurrent Hearing and Genetic Screening of 180,469 Neonates with Follow-up in Beijing, China

Pu Dai, Li Hui Huang, Guo Jian Wang, Xue Gao, Chun Yan Qu, Xiao Wei Chen, Fu Rong Ma, Jie Zhang, Wan Li Xing, Shu Yan Xi, Bin Rong Ma, Ying Pan, Xiao Hua Cheng, Hong Duan, Yong Yi Yuan, Li Ping Zhao, Liang Chang, Ru Zhen Gao, Hai Hong Liu, Wei ZhangSha Sha Huang, Dong Yang Kang, Wei Liang, Ke Zhang, Hong Jiang, Yong Li Guo, Yi Zhou, Wan Xia Zhang, Fan Lyu, Ying Nan Jin, Zhen Zhou, Hong Li Lu, Xin Zhang, Ping Liu, Jia Ke, Jin Sheng Hao, Hai Meng Huang, Di Jiang, Xin Ni, Mo Long, Luo Zhang, Jie Qiao, Cynthia Casson Morton, Xue Zhong Liu, Jing Cheng, De Min Han

Research output: Contribution to journalArticlepeer-review

22 Scopus citations


Concurrent hearing and genetic screening of newborns is expected to play important roles not only in early detection and diagnosis of congenital deafness, which triggers intervention, but also in predicting late-onset and progressive hearing loss and identifying individuals who are at risk of drug-induced HL. Concurrent hearing and genetic screening in the whole newborn population in Beijing was launched in January 2012. This study included 180,469 infants born in Beijing between April 2013 and March 2014, with last follow-up on February 24, 2018. Hearing screening was performed using transiently evoked otoacoustic emission (TEOAE) and automated auditory brainstem response (AABR). For genetic testing, dried blood spots were collected and nine variants in four genes, GJB2, SLC26A4, mtDNA 12S rRNA, and GJB3, were screened using a DNA microarray platform. Of the 180,469 infants, 1,915 (1.061%) were referred bilaterally or unilaterally for hearing screening; 8,136 (4.508%) were positive for genetic screening (heterozygote, homozygote, or compound heterozygote and mtDNA homoplasmy or heteroplasmy), among whom 7,896 (4.375%) passed hearing screening. Forty (0.022%) infants carried two variants in GJB2 or SLC26A4 (homozygote or compound heterozygote) and 10 of those infants passed newborn hearing screening. In total, 409 (0.227%) infants carried the mtDNA 12S rRNA variant (m.1555A>G or m.1494C>T), and 405 of them passed newborn hearing screening. In this cohort study, 25% of infants with pathogenic combinations of GJB2 or SLC26A4 variants and 99% of infants with an m.1555A>G or m.1494C>T variant passed routine newborn hearing screening, indicating that concurrent screening provides a more comprehensive approach for management of congenital deafness and prevention of ototoxicity.

Original languageEnglish (US)
Pages (from-to)803-812
Number of pages10
JournalAmerican journal of human genetics
Issue number4
StatePublished - Oct 3 2019


  • aminoglycoside antibiotics
  • deafness genes
  • genetic deafness
  • habilitation
  • late-onset hearing loss
  • microarray
  • newborn genetic screening
  • newborn hearing screening
  • ototoxicity
  • pathogenic variant

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)


Dive into the research topics of 'Concurrent Hearing and Genetic Screening of 180,469 Neonates with Follow-up in Beijing, China'. Together they form a unique fingerprint.

Cite this